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Transfusion and iron chelation therapy revolutionised survival and reduced morbidity in patients with transfusion-dependent
beta thalassaemia major. Despite these improvements, cardiac disease remained the most common cause of death in those
patients. Recently the ability to determine the degree of cardiac iron overload, through cardiac magnetic resonance imaging
(CMR) has allowed more logical approaches to iron removal, particularly from the heart. The availability of two oral chelators,
deferiproneanddeferasiroxhasreducedtheneedfortheinjectablechelatordeferrioxamineandanadditionalbeneﬁthasbeenthat
deferiprone has been shown to be more cardioprotective than deferrioxamine. This review on the prevention of cardiac disease
makes recommendations on the chelation regime that would be desirable for patients according to their cardiac iron status as
determined by CMR determined by CMR. It also discusses approaches to chelation management should CMR not be available.
Copyright © 2009 Athanassios Aessopos et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
In beta thalassaemia major, transfusion and iron chelation
therapy have signiﬁcantly improved survival and reduced
morbidity [1, 2]. However, heart complications still rep-
resent signiﬁcant morbidity and remain the leading cause
of mortality in transfusion-dependent thalassaemia (TM)
patients [2]. In some cases this was because of the diﬃculty
inacceptingthechelationtreatment,whichwascumbersome
[3], and also occurred even in some patients who accepted
the chelation therapy well [4, 5].
Today, three chelators are available for body iron reduc-
tion in transfusion-dependent anaemias. Deferrioxamine,
the injectable form, has been available for almost 40 years,
deferiprone, the ﬁrst oral iron chelator, was licensed in
Europe since 1999 and recently deferasirox has been licensed
in many countries.
Knowledge derived by recent MRI (CMR) studies which
also assessed cardiac function showed that all patients with
reduced LV function had cardiac iron overload and in many
cases this was severe [6–9]. Therefore, the ability to assess
cardiac iron by MRI and greater choices in iron chelation
have revolutionised the approach to management of trans-
fusion iron overload with the ability to appropriately tailor
iron chelation therapy and promises improved survival.
The suggested iron chelation regimes available till
recently, that is, with desferrioxamine at 30–40mg/kg body
weight per infusion, 8–10 hours per infusion 5–7 days
per week, improved survival and reduced morbidity [10].
However, varying compliance and other factors resulted in
continuing presentation of cardiac dysfunction and prema-
ture cardiac deaths.
2. IronLoadand PredictiveFactorsof
Heart Injury from Iron
For many years, prediction of potential heart iron injury in
TM patient was considered necessary in order to assess the
eﬃcacy of the treatment regimes, particularly the chelation
therapy and to propose any modiﬁcation. Ferritin levels, and
liver iron concentrations (LICs) were the standard surrogate
markers used. Assessment of cardiac function particularly by2 Advances in Hematology
echocardiographyiscertainlyimportantbutoflimitedvalue,
because, usually, once changes are seen, the patients already
have established cardiomyopathy though, in some circum-
stances, there are some parameters that can be determined
with echocardiography that can predict that the patient is
iron overloaded such as the total diameter index. The latter
is calculated by adding the ASE end-diastolic measurements
of the RV diameter, the intraventricular septum thickness,
the LV diameter, and the posterior wall thickness divided by
BSA. A total diameter index (Tdi) >5.57cms/m2 is highly
speciﬁc for predicting cardiac iron (91.4%) but only had a
low sensitivity (31.8%) [11].
In two recent studies, one of which assessed most recent
[9] and one of which assessed highest, lowest, mean 5
year, and most recent ferritin [8], there was a statistically
signiﬁcant relationship of ferritin to MRI-assessed cardiac
iron but no predictive value between the two indices.
Until recently, the LIC was given great signiﬁcance with
respecttotheriskofcardiacdiseaseanditwasrecommended
that levels >12mg/gm dry weight were associated with
cardiac death [12]. However, in one study on 58 transfusion-
dependent patients, aged between 10–45 years, the majority
of whom had thalassaemia major and who were on regular
chelation therapy with desferrioxamine, it was demonstrated
that LIC (by biopsy) was not related to cardiac dysfunction
as assessed by stress MUGA, [13] in that both the resting
LVEF and the increase in LVEF after exercise stress showed
no statistical relationship to the LIC. In another large study
from Torino, 652 patients with thalassaemia major aged
between 1–27 years, the LIC, as estimated by SQUID and
echocardiography ﬁndings, showed similar lack of relation-
ship [14]. These ﬁndings have been elucidated by recent MRI
studies. One did not show statistical signiﬁcance between
LIC and cardiac iron and the others did, while there was
no predictive value between them [6–9]. Therefore, using
LIC as a predictor of cardiac mortality can be misleading.
Caution should be exercised, particularly in patients with
satisfactory ferritin levels and LIC as if they are low, both
the patients and their physician may believe that the patient
is protected from heart disease and it is not realised that
patients with such levels may have excessive cardiac iron
andneedintensiﬁcationofchelationtherapy[8].Irrespective
of this, major eﬀorts should be made to maintain low
LICs because high levels are potentially dangerous and are
associated with other morbidities such as increased risk of
siderophore bacterial infections, cirrhosis, and hepatoma.
As there was no particular examination giving a real
indication of cardiac risk, the ability to determine cardiac
iron, was therefore, crucial. Cardiac biopsy is invasive and
inaccurate[15,16],therefore,theabilitytoassesscardiaciron
noninvasively, reproducibly, and accurately was imperative.
Cardiac magnetic resonance imaging (CMR) has oﬀered that
capability. A number of studies have demonstrated the value
ofCMRinindirectassessmentofcardiacironoverload(T2∗)
and function parameters [17–21]. Many other centres are
instituting either the same or similar MRI techniques. The
resultsappeartobecomparableusingdiﬀerentmachinesand
indiﬀerentcountries[22].Theyarereproducibleandrobust,
provided that the T2∗ method is used and the area measured
is the intraventricular septum [23]. The classiﬁcation of
patients is that those with T2∗ > 20msecs are regarded as
nothavingcardiaciron[6,8,9].ThosewithT2∗ between10–
20msec have mild-to-moderate cardiac iron load and those
<10msecs are considered to have heavy cardiac iron load.
3. Chelation Treatment for Prevention of
Iron Induced Heart Disease
ChelationtreatmenttodayshouldbeguidedbyMRIﬁndings
if the technique is available. In the presence of excess cardiac
and/or hepatic iron, treatment strategies include increase
of the dose and/or frequency of desferrioxamine, switch to
oral chelators in maximal permissible doses (deferiprone or
deferasirox) depending on the degree of cardiac iron load
or to the combination of deferiprone with desferrioxamine,
provided there are no contraindications to their use [24].
With respect to hepatic iron removal, the eﬃcacy of the
two oral chelators is at least equal to the standard doses of
desferrioxamine [25–27]. Recent and ongoing studies have
demonstrated that deferiprone, which is a small molecule
that permeates all tissues, is more eﬃcient in removing
cardiac iron and improving cardiac function than desfer-
rioxamine [25, 26]. Clinical studies with deferasirox are
currently ongoing with respect to removal of cardiac iron.
As yet, there are no studies with combinations of deferasirox
and desferrioxamine so this therapeutic regime cannot be
recommended at this stage.
According to the current knowledge and based on the
CMRﬁndings,thesuggestedchelationregimesareasfollows.
3.1. Acceptable Cardiac Iron. For patients with T2∗ greater
than 20msec, the therapeutic strategy should be continua-
tion of monotherapy with either desferrioxamine or either
of the available oral chelators (deferiprone and desferasirox)
with regular followup. For patients convenience, desferriox-
amine administration may be converted to either of the two
oral chelators.
3.2. Mild-to-Moderate Cardiac Iron Loading. T2∗ values
between 10–20msec are considered to reﬂect a mild-to-
moderately iron-loaded myocardium. Bearing in mind that
the patients may be at risk of developing cardiac problems
under stress such as infections, clearing myocardial tissue
from iron seems to be a rational target. Therefore, com-
bined treatment for these patients should not be a priori
excluded. Patients have presented with LV dysfunction at
levels of T2∗ of 15msec, without any precipitating factors
[8]. Therefore, if T2∗ is ≤15msec, combination chelation
therapy is recommended [24]. However, questions still exist,
regarding the frequency and the amount of desferrioxamine
administration that is appropriate in a combined regimen. A
dose of 35–40mg/kg/day three-four times weekly combined
with deferiprone at a dose of 75mg/kg/day seems to be
reasonable. In patients with T2∗ 15–20msec, monotherapy
with either deferiprone or deferasirox together with careful
followup are available options [25, 26]. As there are no
published trials, at present available, on the eﬃcacy ofAdvances in Hematology 3
deferasirox in removing cardiac iron, if it is to be prescribed,
it is advisable that MRI followup be more frequent than
if deferrioxamine and deferiprone are prescribed. Patients
treated up to the time of the MRI with desferrioxamine in
this category and who availed themselves of that treatment
satisfactorily should not be on monotherapy with that
compound, as deferrioxamine was inadequate at preventing
the iron accumulation in the heart and may indicate some
type of resistance to its eﬃcacy in the heart within that
patient.
3.3. Heavy Cardiac Iron Load . Patients with T2∗ < 10msec
are considered to have severe iron overload and this category
includes most patients with reduced left ventricular (LV)
function. Even those patients with normal ejection fraction
in this category are considered to be at a great risk of
developing cardiac dysfunction. Thus, all patients in this
category have a strong indication for combined chelation
treatment. The doses of deferrioxamine should be approx-
imately 50mg/kg/subcutaneous infusion up to 7 days per
week if tolerated and the deferiprone should be given at
doses between 75–100mg/kg/day in three divided doses. If
the use of deferiprone is contraindicated, then the patients
should be treated with intensive desferrioxamine therapy,
either through continuous infusions through an indwelling
catheter or by subcutaneous continuous infusions [28].
Any treatment modiﬁcation should be followed by close
monitoring. Should any serious adverse eﬀect present as a
consequence of the administration of a particular chelator,
appropriate guidelines as to its continued use should be
followed.
If treatment has ultimately modiﬁed the CMR patient’s
classiﬁcation, then it may be adjusted as discussed earlier
according to the changes in CMR values.
3.4. Guidelines If MRI Is Not Available. In countries where
MRI is not available, then all the patients’ traditional
parameters need to be analysed, (ferritins, liver iron con-
centrations) as well as ECG and echocardiogram, taking
into account the above-discussed limitations. These may
serve as a guide to treatment. In general, iron-related
cardiomyopathy rarely appears before the age of about 14
years. Therefore, until that age, the choice of chelator that
should be recommended depends on those parameters and
which of the three chelators will be more acceptable and
tolerable for the patient and his/her family.
A recent study from Italy has shown that patients who
continued treatment with deferrioxamine had a greater
incidence of cardiomyopathy with greater cardiac-related
mortality than patients who were changed to deferiprone
[29]. This diﬀerence should be considered in patients who
do not have access to CMR in determining which chelator
would be most suitable for patients.
Furthermore, according to the knowledge from MRI
studies in countries where followup of patients occurs, up
to 65% of patients have cardiac iron load. In Sardinia,
1 3 %h a ds e v e r ec a r d i a ci r o no v e r l o a d[ 9]. In our study,
48% of patients have T2∗ < 15msecs [8]. In countries
where patients compliance to treatment is inadequate, there
was poor availability of chelation and/or the followup was
not well organized, the percentage of cardiac iron-loaded
patients is likely to be higher. Therefore, for patients who
have never had optimal care, it is very likely the patients
will have cardiac iron load and intensive chelation as the
treatment of choice. In patients who have been poorly
chelated, the risk of chelation toxicity is minimal and would
only be likely to occur after prolonged therapy, however, it is
importanttobevigilantforsuchcomplications.MRIismore
necessary for those patients who have had good chelation
therapy but who are at risk of chelation inadequacy with
respect to the heart and for those who have had treatment
modiﬁcation in order to follow the eﬃcacy of the changed
chelation regime.
4. Conclusions on Preventionof Heart Disease
This genetic defect that was formerly almost universally fatal
has been revolutionised with the availability of adequate
chelation therapy and more recently with other important
advances.
It remains important, practically, to aim to maintain
low LICs and ferritin levels, particularly as the latter are
easily accessible and assessable. Similarly, echocardiography
should remain a routine tool as it does have some predictive
value and can also be used to monitor patients in whom
intensiﬁcation of chelation therapy has been instituted.
CMR can be particularly helpful in identifying all TM
patients at risk of developing heart disease by assessing
the cardiac iron load. Chelation therapy can be tailored to
remove the excess heart iron. Attention to patient’s continu-
ous compliance with adequate chelation is mandatory.
The deﬁnite ability to know and reduce cardiac iron
as well as improvement in cardiac function that has been
reported should certainly lead to even further signiﬁcant
reductionincardiacmortalityandmorbidity.Insituationsin
whichCMRisnotavailable,dataavailablefromothercentres
can help the clinicians with their decision as to which iron
chelator to recommend for each individual patient.
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